The online version of this article (doi:10.1186/1475-2840-11-42) contains supplementary material, which is available to authorized users.
The authors have no conflict of interest to declare.
S.K.P. designed the study, performed the laboratory work, analysed and interpreted the data, wrote the manuscript, and reviewed and edited the manuscript. B.W. acquired, analysed and interpreted the data, and reviewed and edited the manuscript. R.J.M, S.G., E.V., M.O, S.P. and G.J. acquired the data and reviewed and edited the manuscript. P.M.S. acquired, analysed and reviewed the manuscript. L.M.B. designed the study, interpreted the data, wrote the manuscript and reviewed and edited the manuscript. All authors read and approved the final manuscript.
Connective tissue growth factor (CTGF) has been implicated in the cardiac and kidney complications of type 2 diabetes, and the CTGF − 945 G/C polymorphism is associated with susceptibility to systemic sclerosis, a disease characterised by tissue fibrosis. This study investigated the association of the CTGF − 945 G/C promoter variant with cardiac complications (left ventricular (LV) hypertrophy (LVH), diastolic and systolic dysfunction) and chronic kidney disease (CKD) in type 2 diabetes.
The CTGF − 945 G/C polymorphism (rs6918698) was examined in 495 Caucasian subjects with type 2 diabetes. Cardiac structure and function were assessed by transthoracic echocardiography. Kidney function was assessed using estimated glomerular filtration rate (eGFR) and albuminuria, and CKD defined as the presence of kidney damage (decreased kidney function (eGFR <60 ml/min/1.73 m2) or albuminuria).
The mean age ± SD of the cohort was 62 ± 14 years, with a body mass index (BMI) of 31 ± 6 kg/m2 and median diabetes duration of 11 years [25th, 75th interquartile range; 5, 18]. An abnormal echocardiogram was present in 73% of subjects; of these, 8% had LVH alone, 74% had diastolic dysfunction and 18% had systolic ± diastolic dysfunction. CKD was present in 42% of subjects. There were no significant associations between the CTGF − 945 G/C polymorphism and echocardiographic parameters of LV mass or cardiac function, or kidney function both before and after adjustment for covariates of age, gender, BMI, blood pressure and hypertension. CTGF − 945 genotypes were not associated with the cardiac complications of LVH, diastolic or systolic dysfunction, nor with CKD.
In Caucasians with type 2 diabetes, genetic variation in the CTGF − 945 G/C polymorphism is not associated with cardiac or kidney complications.
Authors’ original file for figure 112933_2012_497_MOESM1_ESM.jpeg
Daniels A, van Bilsen M, Goldschmeding R, van der Vusse GJ, van Nieuwenhoven FA: Connective tissue growth factor and cardiac fibrosis. Acta Physiol (Oxf). 2009, 195: 321-338. 10.1111/j.1748-1716.2008.01936.x. CrossRef
Candido R, Forbes JM, Thomas MC, Thallas V, Dean RG, Burns WC, Tikellis C, Ritchie RH, Twigg SM, Cooper ME, Burrell LM: A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res. 2003, 92: 785-792. 10.1161/01.RES.0000065620.39919.20. CrossRefPubMed
Way KJ, Isshiki K, Suzuma K, Yokota T, Zvagelsky D, Schoen FJ, Sandusky GE, Pechous PA, Vlahos CJ, Wakasaki H, King GL: Expression of connective tissue growth factor is increased in injured myocardium associated with protein kinase C beta2 activation and diabetes. Diabetes. 2002, 51: 2709-2718. 10.2337/diabetes.51.9.2709. CrossRefPubMed
Srivastava PM, Calafiore P, Macisaac RJ, Patel SK, Thomas MC, Jerums G, Burrell LM: Prevalence and predictors of cardiac hypertrophy and dysfunction in patients with Type 2 diabetes. Clin Sci (Lond). 2008, 114: 313-320. 10.1042/CS20070261. CrossRef
Riser BL, Denichilo M, Cortes P, Baker C, Grondin JM, Yee J, Narins RG: Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. J Am Soc Nephrol. 2000, 11: 25-38. PubMed
Roestenberg P, van Nieuwenhoven FA, Wieten L, Boer P, Diekman T, Tiller AM, Wiersinga WM, Oliver N, Usinger W, Weitz S, Schlingemann RO, Goldschmeding R: Connective tissue growth factor is increased in plasma of type 1 diabetic patients with nephropathy. Diabetes Care. 2004, 27: 1164-1170. 10.2337/diacare.27.5.1164. CrossRefPubMed
Nguyen TQ, Tarnow L, Jorsal A, Oliver N, Roestenberg P, Ito Y, Parving HH, Rossing P, van Nieuwenhoven FA, Goldschmeding R: Plasma connective tissue growth factor is an independent predictor of end-stage renal disease and mortality in type 1 diabetic nephropathy. Diabetes Care. 2008, 31: 1177-1182. 10.2337/dc07-2469. CrossRefPubMed
Fonseca C, Lindahl GE, Ponticos M, Sestini P, Renzoni EA, Holmes AM, Spagnolo P, Pantelidis P, Leoni P, McHugh N, Stock CJ, Shi-Wen X, Denton CP, Black CM, Welsh KI, du Bois RM, Abraham DJ: A polymorphism in the CTGF promoter region associated with systemic sclerosis. N Engl J Med. 2007, 357: 1210-1220. 10.1056/NEJMoa067655. CrossRefPubMed
Patel SK, Wai B, Ord M, Macisaac RJ, Grant S, Velkoska E, Panagiotopoulos S, Jerums G, Srivastava PM, Burrell LM: Association of ACE2 genetic variants with blood pressure, left ventricular mass, and cardiac function in caucasians with type 2 diabetes. Am J Hypertens. 2012, 25: 216-222. 10.1038/ajh.2011.188. CrossRefPubMed
American Diabetes Association: Standards of medical care in diabetes--2012. Diabetes Care. 2012, 35 (Suppl 1): S11-S63.
Brosius FC, Hostetter TH, Kelepouris E, Mitsnefes MM, Moe SM, Moore MA, Pennathur S, Smith GL, Wilson PW: Detection of chronic kidney disease in patients with or at increased risk of cardiovascular disease: a science advisory from the American Heart Association Kidney And Cardiovascular Disease Council; the Councils on High Blood Pressure Research, Cardiovascular Disease in the Young, and Epidemiology and Prevention; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: developed in collaboration with the National Kidney Foundation. Circulation. 2006, 114: 1083-1087. 10.1161/CIRCULATIONAHA.106.177321. PubMed
Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ: Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005, 18: 1440-1463. 10.1016/j.echo.2005.10.005. CrossRefPubMed
Srivastava PM, Thomas MC, Calafiore P, MacIsaac RJ, Jerums G, Burrell LM: Diastolic dysfunction is associated with anaemia in patients with Type II diabetes. Clin Sci (Lond). 2006, 110: 109-116. 10.1042/CS20050184. CrossRef
International HapMap Consortium: The International HapMap Project. Nature. 2003, 426: 789-796. 10.1038/nature02168. CrossRef
Rueda B, Simeon C, Hesselstrand R, Herrick A, Worthington J, Ortego-Centeno N, Riemekasten G, Fonollosa V, Vonk MC, van den Hoogen FH, Sanchez-Roman J, Aguirre-Zamorano MA, Garcia-Portales R, Pros A, Camps MT, Gonzalez-Gay MA, Gonzalez-Escribano MF, Coenen MJ, Lambert N, Nelson JL, Radstake TR, Martin J: A large multicentre analysis of CTGF −945 promoter polymorphism does not confirm association with systemic sclerosis susceptibility or phenotype. Ann Rheum Dis. 2009, 68: 1618-1620. 10.1136/ard.2008.100180. PubMedCentralCrossRefPubMed
Dendooven A, Nguyen TQ, Brosens L, Li D, Tarnow L, Parving HH, Rossing P, Goldschmeding R: The CTGF -945GC polymorphism is not associated with plasma CTGF and does not predict nephropathy or outcome in type 1 diabetes. J Negat Results Biomed. 2011, 10: 4-10.1186/1477-5751-10-4. PubMedCentralCrossRefPubMed
Wang B, Carter RE, Jaffa MA, Nakerakanti S, Lackland D, Lopes-Virella M, Trojanowska M, Luttrell LM, Jaffa AA: Genetic variant in the promoter of connective tissue growth factor gene confers susceptibility to nephropathy in type 1 diabetes. J Med Genet. 2010, 47: 391-397. 10.1136/jmg.2009.073098. CrossRefPubMed
Pivovarova O, Fisher E, Dudziak K, Ilkavets I, Dooley S, Slominsky P, Limborska S, Weickert MO, Spranger J, Fritsche A, Boeing H, Pfeiffer AF, Rudovich N: A polymorphism within the connective tissue growth factor (CTGF) gene has no effect on non-invasive markers of beta-cell area and risk of type 2 diabetes. Dis Markers. 2011, 31: 241-246. PubMedCentralCrossRefPubMed
Opstad TB, Pettersen AA, Arnesen H, Seljeflot I: Circulating levels of IL-18 are significantly influenced by the IL-18 +183 A/G polymorphism in coronary artery disease patients with diabetes type 2 and the metabolic syndrome: an Observational Study. Cardiovasc Diabetol. 2011, 10: 110-10.1186/1475-2840-10-110. PubMedCentralCrossRefPubMed
Cresci S, Wu J, Province MA, Spertus JA, Steffes M, McGill JB, Alderman EL, Brooks MM, Kelsey SF, Frye RL, Bach RG: Peroxisome proliferator-activated receptor pathway gene polymorphism associated with extent of coronary artery disease in patients with type 2 diabetes in the bypass angioplasty revascularization investigation 2 diabetes trial. Circulation. 2011, 124: 1426-1434. 10.1161/CIRCULATIONAHA.111.029173. PubMedCentralCrossRefPubMed
Kramer CM, Barkhausen J, Flamm SD, Kim RJ, Nagel E: Standardized cardiovascular magnetic resonance imaging (CMR) protocols, society for cardiovascular magnetic resonance: board of trustees task force on standardized protocols. J Cardiovasc Magn Reson. 2008, 10: 35-10.1186/1532-429X-10-35. PubMedCentralCrossRefPubMed
- The CTGF gene −945 G/C polymorphism is not associated with cardiac or kidney complications in subjects with type 2 diabetes
Sheila K Patel
Richard J MacIsaac
Piyush M Srivastava
Louise M Burrell
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II